A new critical study in the field of diabetes management shows the problems that almost half of the patients on Ozempic-Mounjaro are having. This study sheds light on the complexities of diabetes care and drug compliance.

A new study says that about half of the people who were given Ozempic Mounjaro, a drug used to treat diabetes, have stopped taking it. These results raise important questions about how well people with diabetes tolerate the medicine.

Many people thought Ozempic Mounjaro would be a great way to treat diabetes, but it has had problems in the real world, and many patients have decided to stop taking it. The study details why this has stopped happening and what it means for patients and healthcare workers.

READ ALSO: Mounjaro vs Ozempic: How do they compare?

For diabetes care to be at its best, it’s essential to understand how these choices are made. The study shows how people with diabetes deal with their lives, taking into account the fact that diabetes is complicated and that many things affect treatment choices.

These are the side effects of Mounjaro and Ozempic, according to the published article on Drugs.com.
In Mounjaro studies, the most commonly reported side effects, compared to a placebo (an inactive agent), are:

• Nausea: 12% to 18% (vs. 4% on placebo)
• Diarrhea: 12% to 17% (vs. 9% on placebo)
• Decreased appetite: 5% to 11% (vs. 1% on placebo)
• Vomiting: 5% to 9% (vs. 2% on placebo)
• Constipation: 6% to 7% (vs. 1% on placebo)
• Heartburn (dyspepsia): 5% to 8% (vs. 3% on placebo)
• Stomach (abdominal) pain: 5% to 6% (vs. 4% on placebo)

In total, 37% to 44% of Mounjaro patients had stomach problems, compared to 20% of control patients. Additionally, 3% to 6.6% of Mounjaro patients stopped treatment because of stomach problems like sickness, vomiting, and/or diarrhea, compared to only 0.4% of placebo patients. Most reports of feeling sick, throwing up, or having diarrhea happened when the amount increased at the beginning of treatment and improved over time.

Other noted side effects of Mounjaro were low blood sugar (hypoglycemia), fast heart rate, allergic reactions, injection site reactions, acute gallbladder disease, and rises in the pancreatic enzymes amylase and lipase.

The most common side effects of Ozempic are:

• Nausea: 16% to 20% (vs. 6% on placebo)
• Diarrhea: 8.5% to 8.8% (vs. 1.9% on placebo)
• Vomiting: 5% to 9.2% (vs. 2.3% on placebo)
• Constipation: 3.1% to 5% (vs. 1.5% on placebo)
• Heartburn (dyspepsia): 2.7% to 3.5% (vs. 1.9% on placebo)
• Stomach (abdominal) pain: 5.7% to 7.3% (vs. 4.6% on placebo)

About 33% to 36% of people who took Ozempic had stomach problems, but only 15% of people who took a fake did. Also, 3.1% to 3.8% of Ozempic patients quit taking it because of stomach problems, while only 0.4% of the placebo group did the same.

Other side effects of Ozempic were low blood sugar, reactions at the injection site, elevated amylase and lipase (pancreas enzymes), cholelithiasis (gallstones), faster heart rate, tiredness, changes in taste, allergic reactions, and dizziness.

READ ALSO: Biden Warns Pharma: High Drug Prices Could Lead To Patent Revocation

Since diabetes is still a big problem worldwide, the study’s results make us want to learn more about how drugs like Ozempic Mounjaro work in real life. This nuanced view adds to ongoing discussions about managing diabetes in a way that fits each person’s wants and problems, since a single method might not work for everyone.

The study stresses how important it is to keep researching, getting patients involved, and working with healthcare providers to improve methods for managing diabetes. It starts a more extensive conversation in the medical community and beyond about improving treatment plans to make life better for people with diabetes.

READ ALSO: Tailored For Life: Exploring A Personalized Lifesaving Treatment – Is This The Future Of Medical Care?